- World Pharma News Home » Published News » Financial
(a free service delivered by FeedBurner)
Genzyme Corp. (NASDAQ: GENZ) reported that preliminary fourth-quarter revenue was $1.08 billion, compared with $1.17 billion in the same period in 2008. For the year, revenue was $4.5 billion compare
read more »
Discuss Add this link to... Bury
Discuss Add this link to... Bury
Pfizer (NYSE: PFE) and Strides Arcolab (BSE: 532531, NSE: STAR) announced a new collaboration, wherein Pfizer will commercialize off-patent sterile injectable and oral products in the United States t
read more »
Discuss Add this link to... Bury
Discuss Add this link to... Bury
Funds To Be Used To Continue Development of Two Drug Candidates Into Phase 2 Human Clinical Trials
read more »
Discuss Add this link to... Bury
Discuss Add this link to... Bury
Nycomed reports continued satisfactory performance in the third quarter 2009, with total net turnover increasing by 0.9% (3.2% in local currencies) to €820.0 million. Pantoprazole sales were resilien
read more »
Discuss Add this link to... Bury
Discuss Add this link to... Bury
Novartis has reached an agreement to acquire an 85% stake in the Chinese vaccines company Zhejiang Tianyuan Bio-Pharmaceutical Co., Ltd. as part of a strategic initiative to build a vaccines industry
read more »
Discuss Add this link to... Bury
Discuss Add this link to... Bury
Novartis announced a USD 1 billion investment over the next five years, increasing R&D activities in China and confirming Novartis' long term commitment to China's further economic development, hea
read more »
Discuss Add this link to... Bury
Discuss Add this link to... Bury
Sales increased by 15% in Danish kroner and by 11% in local currencies:
- Sales of modern insulins increased by 28% (24% in local currencies).
- Sales of NovoSeven® increased by 15% (11% in local c read more »
Discuss Add this link to... Bury
- Sales of modern insulins increased by 28% (24% in local currencies).
- Sales of NovoSeven® increased by 15% (11% in local c read more »
Discuss Add this link to... Bury
Revenue in the third quarter increased by 10 percent at CER, but was up 5 percent on an actual basis as a result of the negative impact of exchange rate movements. Revenue benefited from strong growt
read more »
Discuss Add this link to... Bury
Discuss Add this link to... Bury
Novartis maintained the strong underlying momentum of 2009 as third-quarter net sales grew 7% in local currencies, while reported net sales rose 3% to USD 11.1 billion as four percentage points of gr
read more »
Discuss Add this link to... Bury
Discuss Add this link to... Bury
Merck KGaA announced that Group total revenues rose 2.7% in the third quarter to € 1,944 million from € 1,893 million in the year-ago quarter as the Pharmaceuticals divisions continued to grow and th
read more »
Discuss Add this link to... Bury
Discuss Add this link to... Bury
